2 completed, 2 unknown, 1 recruiting. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Unknown 2, Recruiting 1 |
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow Thymalfasin: new trials by email Literature Review of Thymalfasin trials Research Report on Thymalfasin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine Thymalfasin (Thymosin alpha 1, Ta1) - Vaccine Response, COVID-19 Vaccine | Phase 1 | Recruiting | The Methodist Hospital Research Institute | 75 | 2024-12-02 | 2026-07-16 |
| First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy Thymalfasin (Thymosin alpha 1, Ta1), SoC (tyrosine kinase inhibitor) - EGFR Mutation Positive Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | SciClone Pharmaceuticals | 188 | 2016-10-01 | 2016-09-19 |
| Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients REP 2139-Ca, Zadaxin, Pegasys - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Replicor Inc. | 12 | 2011-08-01 | 2016-01-05 |
| Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies Thymosin alpha 1 - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | University Of Perugia | 9 | 2007-12-01 | 2007-12-24 |
| The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection Thymalfasin, Interleukin-2, Polyethylene Glycolated, Zidovudine - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 12 | 2008-07-30 |
Acquired Immunodeficiency Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · HIV Infections (1) · Hematologic Neoplasms (1) · Hepatitis B, Chronic (1)
National Institute of Allergy and Infectious Diseases (NIAID) (1) · Replicor Inc. (1) · SciClone Pharmaceuticals (1) · The Methodist Hospital Research Institute (1) · University Of Perugia (1)
Italy (2) · United States (2) · Bangladesh (1)
Andrea Velardi, Prof (1) · Mamun Al-Mahtab, MD (1) · Prof. Paolo Marchetti, MD (1) · TC Merigan (1)